Join to View Full Profile
525 E 68th St# F-900New York, NY 10065
Phone+1 212-746-5493
Fax+1 212-746-8941
Dr. Bander is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ConnecticutResidency, Urology, 1978 - 1980- University of Connecticut School of MedicineInternship, Transitional Year, 1977 - 1978
NYU Grossman School of MedicineResidency, Surgery, 1977 - 1977- NYU Grossman School of MedicineResidency, Surgery, 1974 - 1976
- Uconn School Of MedicineClass of 1974
Certifications & Licensure
NY State Medical License 1976 - 2022
American Board of Urology Urology
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 1998 Jun 01
Publications & Presentations
PubMed
- Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level Analysis.Judith Stangl-Kremser, Andres Ricaurte-Fajardo, Sandra Huicochea Castellanos, Alexander Martinez-Fundichely, Michael Sun
The Prostate. 2025-04-01 - 10 citationsProstate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study o...Scott T Tagawa, Charlene Thomas, A Oliver Sartor, Michael Sun, Judith Stangl-Kremser
Journal of Clinical Oncology. 2024-03-01 - 6 citationsProstate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer.Lena M Unterrainer, Jeremie Calais, Neil H Bander
Annual Review of Medicine. 2024-01-29
Press Mentions
AACR: Philip Kantoff Discusses Convergent's Unique Path to Treating Prostate CancerApril 14th, 2022- Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph OsborneApril 7th, 2022
- AIkido Pharma Has Pending Data Results on June 4th, with Strongest Balance Sheet in Its History While Trading Below CashMay 20th, 2021
- Join now to see all
Grant Support
- PH. I Humanized MAB Huj591-Dota-177lu/ Relapsed Prostate CancerNational Center For Research Resources2004
- Monoclonal Antibody Muj591 Patients W/ Hormone Independant Prostate CancerNational Center For Research Resources1999–2001
- Phase I/Ii/ 131 Iodine MAB Prost 30/Patients W/Advanced Prostate CancerNational Center For Research Resources1998–2000
- Phase 1 Trial Of Monoclonal Antibody F31 In Renal CancerNational Center For Research Resources1997–2000
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
